Tyrosinaemia type I — an update
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Tyrosinaemia type I is a recessively inherited disorder caused by a deficiency of fumarylacetoacetase (FAH), the last enzyme in tyrosine degradation. The presumed toxic agents are fumaryl‐ and maleylacetoacetate which are converted to succinylacetone (SA), a metabolite found in increased amounts in urine and plasma of the patients. The major clinical features are progressive liver damage and renal tubular defects with hypophosphataemic rickets. Renal tubular dysfunctions with secondary rickets may be lacking altogether, even in chronic patients. Hepatocellular carcinoma is a major cause of death in the chronic form. Diagnosis of the disorder is made by assay of SA in urine and serum and by determination of FAH in lymphocytes or fibroblasts. Prenatal diagnosis is performed by SA assay in amniotic fluid supernatant and FAH analysis in cultured amniotic fluid cells or chorionic villus material. Presence of a ‘pseudodeficiency’ gene for FAH prevents prenatal diagnosis by enzyme analysis in some families, and this gene also precludes identification of heterozygotes outside tyrosinaemia families. Immunoblot analyses show that acute patients and some chronic patients lack immunoreactive FAH protein. cDNA probes for FAH have been developed and several polymorphisms related to the FAH gene have been reported, which may allow prenatal diagnosis in families with complex genotypes. The gene for FAH has been mapped to chromosome 15 q23–q25. Liver transplantation is the ultimate treatment; most patients continue to excrete SA in urine after liver transplantation and therefore there is a possibility of kidney disease after transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447 · cited 2×
“primary defect in tyrosinaemia was a breakthrough in the understanding of the disorder (Lindblad et al., 1977).”
BackgroundThe occurrence of hepatoma in the chronic form of hereditary tyrosinemia
Weinberg, A. G., Mize, C. E., & Worthen, H. G. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)80259-4 · Cited by 283
Biochemical studies on the enzymatic deficiencies in hereditary tyrosinemia
Berger, R., van Faassen, H., & Smith, G. P. A. (1983) · Clinica Chimica Acta · doi:10.1016/0009-8981(83)90191-2 · Cited by 45 · cited 1×
“Fumarylacetoacetate and SA have not been found to inhibit the dioxygenase directly (Berger et al., 1983).”
BackgroundBerger, R., Van Faassen, H., Taanman, J. W., De Vries, H., & Agsteribbe, E. (1987) · Pediatric Research · doi:10.1203/00006450-198710000-00005 · Cited by 37
Cited by
Tyrosine biosynthesis, metabolism, and catabolism in plants
Schenck, C. A., & Maeda, H. A. (2018) · Phytochemistry · doi:10.1016/j.phytochem.2018.02.003 · Cited by 286
Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102
Self-citationDisorders of Tyrosine Metabolism
Chakrapani, A., & Holme, E. (2006) · Inborn Metabolic Diseases · doi:10.1007/978-3-540-28785-8_18 · Cited by 52
Epov, L., Srugo, I., Kassis, I., Bar‐Joseph, G., Mandel, H., & Kugelman, A. (2010) · Acta Paediatrica · doi:10.1111/j.1651-2227.2010.01901.x · Cited by 4
Metadata
- Authors
- Kvittingen, E. A.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 1991-07
- Volume
- 14
- Issue
- 4
- Pages
- 554-562
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W1972405529
- Cited by
- 58
- References
- 4
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.